Orion Oyj (HEL:ORNBV)

Market Cap	9.49B +29.4%
Revenue (ttm)	1.89B +22.5%
Net Income	500.30M +51.7%
EPS	3.56 +51.5%
Shares Out	140.69M
PE Ratio	18.96
Forward PE	18.26
Dividend	1.80 (2.67%)
Ex-Dividend Date	Mar 25, 2026

Volume	74,976
Average Volume	214,520
Open	66.70
Previous Close	67.45
Day's Range	65.80 - 68.70
52-Week Range	46.62 - 75.30
Beta	0.36
RSI	45.25
Earnings Date	Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,029
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.